These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 18278833)

  • 21. [Clinical study of etanercept for treating ankylosing spondylitis].
    Liang LQ; Zhan ZP; Ye YJ; Fu D; Xu HS; Yang XY
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1349-51. PubMed ID: 18753057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of the spondyloarthritis research consortium of Canada magnetic resonance imaging spinal inflammation index: is it necessary to score the entire spine?
    Maksymowych WP; Dhillon SS; Park R; Salonen D; Inman RD; Lambert RG
    Arthritis Rheum; 2007 Apr; 57(3):501-7. PubMed ID: 17394179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of anti-TNF in patients with spondyloarthritis in absence of any imaging sign.
    Bisson-Vaivre A; Alcaix D; Zarnitsky C; Pueyo L; Daragon A; Lanfant-Weybel K; Dacher JN; Vittecoq O; Le Loët X; Goëb V
    Joint Bone Spine; 2013 May; 80(3):280-6. PubMed ID: 23021158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis.
    van der Heijde D; Sieper J; Maksymowych WP; Dougados M; Burgos-Vargas R; Landewé R; Rudwaleit M; Braun J;
    Ann Rheum Dis; 2011 Jun; 70(6):905-8. PubMed ID: 21540200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease.
    Mathieu S; Joly H; Baron G; Tournadre A; Dubost JJ; Ristori JM; Lusson JR; Soubrier M
    Rheumatology (Oxford); 2008 Aug; 47(8):1203-7. PubMed ID: 18524805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies.
    Kievit W; Fransen J; Adang EM; Kuper HH; Jansen TL; De Gendt CM; De Rooij DJ; Brus HL; van de Laar MA; Van Riel PC
    Ann Rheum Dis; 2009 Jun; 68(6):844-9. PubMed ID: 18625616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index.
    Maksymowych WP; Mallon C; Morrow S; Shojania K; Olszynski WP; Wong RL; Sampalis J; Conner-Spady B
    Ann Rheum Dis; 2009 Jun; 68(6):948-53. PubMed ID: 18524792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and drug survival of anti-tumour necrosis factor-alpha therapies in patients with non-radiographic axial spondyloarthritis: an observational cohort study from Southern Sweden.
    Gulfe A; Kapetanovic MC; Kristensen LE
    Scand J Rheumatol; 2014; 43(6):493-7. PubMed ID: 25145283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Editorial review: how early should ankylosing spondylitis be treated with a tumor necrosis factor-blocker?
    Haibel H; Sieper J
    Curr Opin Rheumatol; 2010 Jul; 22(4):388-92. PubMed ID: 20473176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.
    Wallman JK; Kapetanovic MC; Petersson IF; Geborek P; Kristensen LE
    Arthritis Res Ther; 2015 Dec; 17():378. PubMed ID: 26703005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of treatments for sacroiliitis in spondyloarthropathy using the Spondyloarthritis Research Consortium Canada scoring system.
    Cui Y; Zheng J; Zhang X; Zeng H; Luo R
    Arthritis Res Ther; 2016 Feb; 18():38. PubMed ID: 26832154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment with tumor necrosis factor inhibitors in axial spondyloarthritis: comparison between private rheumatology practices and academic centers in a large observational cohort.
    Ciurea A; Weber U; Stekhoven D; Scherer A; Tamborrini G; Bernhard J; Toniolo M; Villiger PM; Zufferey P; Kissling RO; Michel BA; Exer P;
    J Rheumatol; 2015 Jan; 42(1):101-5. PubMed ID: 25362654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations.
    Song IH; Rudwaleit M; Listing J; Sieper J
    Ann Rheum Dis; 2009 Nov; 68(11):1701-7. PubMed ID: 19029168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation.
    Maksymowych WP; Chiowchanwisawakit P; Clare T; Pedersen SJ; Østergaard M; Lambert RG
    Arthritis Rheum; 2009 Jan; 60(1):93-102. PubMed ID: 19116919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab.
    Visvanathan S; Wagner C; Marini JC; Baker D; Gathany T; Han J; van der Heijde D; Braun J
    Ann Rheum Dis; 2008 Apr; 67(4):511-7. PubMed ID: 17644552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Consistently Good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trial.
    Song IH; Hermann KG; Haibel H; Althoff CE; Poddubnyy D; Listing J; Weiß A; Buß B; Freundlich B; Lange E; Alten R; Rudwaleit M; Sieper J
    J Rheumatol; 2014 Oct; 41(10):2034-40. PubMed ID: 25028375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis.
    Choi ST; Kim JH; Kang EJ; Lee SW; Park MC; Park YB; Lee SK
    Rheumatology (Oxford); 2008 Dec; 47(12):1775-9. PubMed ID: 18854347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment.
    Briot K; Gossec L; Kolta S; Dougados M; Roux C
    J Rheumatol; 2008 May; 35(5):855-61. PubMed ID: 18381782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 2014 Update of the Canadian Rheumatology Association/spondyloarthritis research consortium of Canada treatment recommendations for the management of spondyloarthritis. Part I: principles of the management of spondyloarthritis in Canada.
    Rohekar S; Chan J; Tse SM; Haroon N; Chandran V; Bessette L; Mosher D; Flanagan C; Keen KJ; Adams K; Mallinson M; Thorne C; Rahman P; Gladman DD; Inman RD
    J Rheumatol; 2015 Apr; 42(4):654-64. PubMed ID: 25684770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Axial spondyloarthritis and ankylosing spondylitis].
    Nordström D; Kauppi M
    Duodecim; 2010; 126(12):1467-74. PubMed ID: 20617750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.